About 50% of prostate cancers carry the gene fusion linking the androgen-regulated serine protease TMPRSS2 with the ETS-transcription factor ERG, resulting in the overexpression of ERG [17, 26, 27]. Here, TMPRSS2 is linked to prostate cancer.